- Home
- LPCV vs LCTX Comparison
LPCV vs LCTX Comparison
Compare LPCV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPCV | LCTX |
|---|---|---|
| Founded | 2025 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.2M | 251.4M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | LPCV | LCTX |
|---|---|---|
| Price | $10.13 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 32.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $4.38 |
| Revenue Next Year | N/A | $10.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $9.89 | $0.88 |
| 52 Week High | $10.13 | $1.99 |
Technical Indicators
Market Signals| Indicator | LPCV | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 49.07 |
| Support Level | $9.97 | $0.89 |
| Resistance Level | N/A | $1.05 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 100.00 | 25.77 |
Price Performance
Historical ComparisonAbout LPCV Launchpad Cadenza Acquisition Corp I Class A Ordinary Share
Launchpad Cadenza Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.